Fate Therapeutics Inc (FATE)

[NY1972]

aßT cells according to
Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY

iPSC-derived aßT, NK, and iNKT cells are currently being tested in phase I clinical trials. The ability to perform (multiplexed) gene editing at the iPSC level and subsequent differentiation into effector populations not only expands the arsenal of ACT but allows for development of ACT utilizing cell types which cannot be efficiently obtained from peripheral blood or engineered and expanded in vitro.

https://www.sciencedirect.com/science/article/abs/pii/S0301472X24005137